Alpelisib als neue Therapieoption bei Hormonrezeptor-positivem, HER2-negativem Brustkrebs - 10 - 2020 - Heftarchiv - AMT
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Novartis: US-Zulassung für Alpelisib | APOTHEKE ADHOC
Detecting and Managing Drug-Induced Diabetes
PDF) Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
Positive Quality Intervention: Management of Alpelisib (Piqray®) Induced Hyperglycemia Description: This PQI is intended to add
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series - Tahj Blow, Parker N. Hyde, John N. Falcone, Aaron Neinstein, Neil Vasan, Ritika Chitkara, Maurice
Patient With a PIK3CA-Positive Tumors Exhibits Hyperglycemia Associated With Alpelisib
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer | Future Oncology
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Leitfaden zur Verringerung von Arzneimittel- und Anwendungsrisiken – Ärzte Piqray® (Alpelisib)
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer | Future Oncology
Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Le | OTT
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study - The Lancet Oncology
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Pa | TCRM
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report | Clinical Diabetes and Endocrinology | Full Text
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
Trial to Assess Alpelisib in Combination with Fulvestrant in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications | Breast Cancer Research | Full Text
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data - Oncology Nurse Advisor
14 days Ambulatory Glucose Profile following start of alpelisib... | Download Scientific Diagram
Studientitel, Nr., Akronym Alpelisib (BYL719) + Exemestan +/- Everolimus bei Patientinnen mit fortgeschrittenem Mammakarzinom P
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | Nature Cancer
Considerations for Management of Alpelisib Induced Hyperglycemia
